|
Jul 23
|
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
|
|
Jun 30
|
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
|
|
Jun 28
|
Positive Signs As Multiple Insiders Buy AN2 Therapeutics Stock
|
|
Feb 24
|
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
|
|
Feb 20
|
AN2 Therapeutics to Participate at Upcoming Investor Conferences
|
|
Aug 28
|
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
May 21
|
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
|
|
Feb 22
|
13 Best Falling Stocks To Buy Right Now
|
|
Jan 12
|
AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares
|
|
Jan 10
|
Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why
|
|
Aug 10
|
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
|
|
May 1
|
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
|